Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - March 27, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 - consisting of the Business Report ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 27, 2025Idorsia Ltd (SIX: IDIA) today announced the ...

Background The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation associated with adverse ...

Japan’s Shionogi (TYO: 4507) yesterday delivered a late-breaking scientific oral presentation at the Conference of Retroviruses and Opportunistic Infections (CROI) 2025 on its ensitrelvir.

1 Chanchlani Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada 2 Mary Heersink School of Global Health and Social Medicine, Faculty of Health Sciences, McMaster ...

March 5 (Reuters) - Merck's (MRK.N), opens new tab injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics (HALO.O ...

Good day and thank you for standing by. Welcome to the Idorsia Full Year 2024 Financial Results Webcast. At this time, all participants are in listen-only mode. After the speakers' presentation ...

Viatris collaboration: Global research and development collaboration, focused on the development and commercialization of selatogrel and cenerimod entered in March 2024. QUVIVIQ™ (daridorexant): ...